SCHEMBL7711323

SCHEMBL7711323

CC1Oc2ccc(CN(Cc3ccc4c(c3)OCO4)C(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 6/20 0.41
HSD17B10 Q99714 4/20 0.39
KDM4E B2RXH2 4/20 0.39
BMP1 P13497 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
CYP3A4 P08684 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
APOBEC3A P31941 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 2/20 0.38
ALOX15 P16050 2/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
GAA P10253 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7710387 0.90 PARP1 (0.44) ALDH1A1SMN1; SMN2TSHRHSD17B10KDM4E
SCHEMBL7704945 0.88 HDAC3 (0.44) ALDH1A1SMN1; SMN2HSD17B10NPSR1ALOX15
SCHEMBL7704907 0.88 HSD17B10 (0.38) SMN1; SMN2TSHRHSD17B10POLBALOX15
SCHEMBL7704932 0.87 HDAC3 (0.35) HSD17B10MAPTALOX15
SCHEMBL7708363 0.86 TP53 (0.35) HSD17B10MAPTALOX15GAAMEN1
SCHEMBL7711422 0.86 HSD17B10 (0.36) ALDH1A1TSHRHSD17B10KDM4EBMP1
SCHEMBL6309617 0.86 HDAC1 (0.43) ALDH1A1SMN1; SMN2HSD17B10NPSR1ALOX15
SCHEMBL7704942 0.85 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2HSD17B10NPSR1POLB
SCHEMBL7711006 0.85 PARP1 (0.36) ALDH1A1SMN1; SMN2TSHRHSD17B10KDM4E
SCHEMBL7704966 0.85 TP53 (0.37) ALDH1A1TSHRHSD17B10KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed